- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05114616
Assessment of Consciousness States with NextSense Ear Bud Devices
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Detection of physiological parameters that define wake and various stages of sleep for clinical and research purposes has for decades relied upon systems that acquire physiological signals by way of multiple surface electrodes conveyed via conductive wires to hardware that amplifies and stores information on a central processing unit (CPU). This restricts or burdens human subjects in such a way that free action or movement is difficult and requires that patients be monitored by trained staff in an accredited sleep laboratory which levies substantial financial cost, can be inconvenient for patients and families, and is labor intensive. Visual scoring of the sleep stages is the gold standard in sleep research and medicine. Sleep scoring is performed visually based on the following signals: (1) electrical activity of the brain assessed via electroencephalogram (EEG), (2) electrical activity resulting from the movement of the eyes and eyelids assessed via electrooculogram (EOG) and (3) muscle tone recorded under the chin (submental) assessed via electromyogram (EMG). Scoring is usually performed according to standardized scoring rules: Rechtschaffen and Kales or the AASM. An expert visually classifies consecutive 30-s epochs of polysomnographic (PSG) data (EEG, EOG and EMG) into wake, rapid eye movement (REM) sleep, and non-REM (NREM) sleep (stages N1-N3). The plot of a sequence of sleep stages is called a hypnogram.
Visual scoring by an expert is time consuming and subjective. Several studies have addressed the interrater reliability and found that correspondence between scorers is less than ideal. The main goal of this project is determine the feasibility of two different wearable technologic devices in differentiating conventional sleep metrics (including wake versus the four different sleep stages) versus those derived from simultaneous gold-standard, in-laboratory PSG methods.
Volunteer participants will undergo an overnight stay in a diagnostic sleep laboratory followed by a next-day maintenance of wakefulness testing (MWT) according to standard AASM protocols. While being monitored by way of multiple, standard surface electrodes on their scalp (EEG monitoring), outer canthus of each eye (EOG monitoring), mentalis (chin) and bilateral anterior tibialis (leg) (EMG monitoring), and torso (electro-cardiogram (EKG) monitoring) during conventional PSG, the NextSense ear-EEG device will be positioned within each external ear canal. In order to increase the homeostatic drive to sleep during MWT the following day (providing greater opportunity to assess biometrics of "sleepiness") the researchers will extend wake four hours past each participant's habitual sleep start time, thereby allowing only 3-4 hours of sleep prior to awakening.
The subsequent day MWT consists of four sessions scheduled at 2-hour intervals during which participants will be asked to remain awake/vigilant, while seated in their room with lights off for 40 minutes. Prior to and following each trial, participants will complete standardized subjective metrics of their sleepiness, and surrogate objective measures of alertness including attention tasks, and the N-back task which is a continuous performance task commonly used to assess working memory and working memory capacity. During the three time intervals separating the four MWT trials, participants will be asked to read and repeat two standard sentences included in the Montreal Cognitive Assessment (MoCA) aloud and the voice audio will be recorded for subsequent analysis. Participants will be asked to wear Ellcie Healthy glasses, concurrent with the NextSense ear-EEG device, during each MWT trial, flanker attention tasks, and text read-aloud tasks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Emory Sleep Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy adults ages 18-60 years of age living within 20 miles of the Emory Sleep Center in Atlanta, Georgia.
- Normal body mass index (BMI) (>= 18.5 and <= 28.0 kg/m^2) at screening visit.
- Has regular sleep-wake habits (e.g., 7-8.5 hours nightly sleep, consistent bed/wake times within 1-2 hours, regular bedtime between 9:30pm-11:30pm, does not oversleep by > 2 hours on weekends).
- Does not require regular sleep aids or wake promoting medications (including some over the counter cold/allergy medications).
Exclusion Criteria:
- Has a history of diagnosed or suspected sleep disorder (e.g., sleep-related breathing disorders, circadian rhythm sleep-wake disorders, central disorders of hypersomnolence, parasomnias, sleep-related movement disorders, disorders of sleep maintenance or initiation) or other medical condition associated with excessive daytime sleepiness.
- Regular caffeine consumption > 200 mg per day (1 cup of coffee = 80-120 mg).
- Has a history of major psychiatric disorder (e.g., major depression, bipolar disorder, schizophrenia) or suicidal ideation.
- Current or recent (within the past 6 months) substance dependence (including nicotine, marijuana, alcohol, or any other substance that is likely to affect sleep).
- Has a history of diagnosed or suspected attention deficit/hyperactivity disorder.
- Has performed as a nighttime shift-worker within the past 6 months.
- Inability to safely tolerate wearing earbuds due to recent injury, skin breakdown, or infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Sleep Study and Daytime MWT
Health volunteers completing one overnight sleep study followed by daytime MWT.
The sleep study will include standard surface electrodes as well as EEGBuds.
Participants will be asked to wear Ellcie Healthy glasses, concurrent with the EEGBuds, during each MWT trial.
|
Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate.
The custom mold is created employing a 3D printer following capture of the geometry unique to each patients' ears with a ring laser scanner to an accuracy of within 0.1 mm.
This design process allows for a custom fit and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality capture of signals reflecting brain activity, and head, and eye movements.
In addition to the custom fit earmold, universal fit earmolds are available as well.
The universal fit earmolds were designed also to allow for comfort and consisten contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
30-second Epoch Related to Wake Stage of Sleep
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
Sleep stage scoring will be derived from 30-second epochs based on American Academy of Sleep Medicine (AASM) scoring criteria for four sleep/wake states, with the outputs from the PSG and the NextSense ear-EEG device being hand scored.
The 30-second epochs related to the wake stage of sleep obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
|
Day 1 (during overnight assessment of the single study visit)
|
|
30-second Epoch Related to N1 Stage of Sleep
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
Sleep stage scoring will be derived from 30-second epochs based on AASM scoring criteria for four sleep/wake states, with the outputs from the PSG and the NextSense ear-EEG device being hand scored.
The 30-second epochs related to the N1 stage of sleep obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
|
Day 1 (during overnight assessment of the single study visit)
|
|
30-second Epoch Related to N2 Stage of Sleep
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
Sleep stage scoring will be derived from 30-second epochs based on AASM scoring criteria for four sleep/wake states, with the outputs from the PSG and the NextSense ear-EEG device being hand scored.
The 30-second epochs related to the N2 stage of sleep obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
|
Day 1 (during overnight assessment of the single study visit)
|
|
30-second Epoch Related to N3 Stage of Sleep
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
Sleep stage scoring will be derived from 30-second epochs based on AASM scoring criteria for four sleep/wake states, with the outputs from the PSG and the NextSense ear-EEG device being hand scored.
The 30-second epochs related to the N3 stage of sleep obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
|
Day 1 (during overnight assessment of the single study visit)
|
|
30-second Epoch Related to Rapid Eye Movement (REM) Stage of Sleep
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
Sleep stage scoring will be derived from 30-second epochs based on AASM scoring criteria for four sleep/wake states, with the outputs from the PSG and the NextSense ear-EEG device being hand scored.
The 30-second epochs related to the REM stage of sleep obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
|
Day 1 (during overnight assessment of the single study visit)
|
|
30-second Epoch Related to Movement Time
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The 30-second epochs related to movement time obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Sleep Onset Latency to Stage N1 Sleep
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
Sleep onset latency to stage N1 sleep is the time it takes in minutes to transition from wakefulness to sleep.
Stage N1 sleep is light sleep which is easy to be awakened from.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Sleep Onset Latency to Stage N2 Sleep
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
Sleep onset latency to stage N2 sleep is the time it takes in minutes to transition deeper sleep.
Stage N2 sleep has physical characteristics of heart rate slowing, body temperature dropping, and the beginning of delta waves.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Rapid Eye Movement (REM) Sleep Latency
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
REM sleep latency is the time it takes in minutes to transition from wakefulness to REM sleep.
REM sleep is the stage when dreaming occurs.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Total Sleep Time
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
Total sleep time is measured in minutes.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Wake After Sleep Onset (WASO)
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
WASO measures wakefulness (in minutes) after sleep onset.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Sleep Efficiency
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
Sleep efficiency is the percentage of time in bed that is spend sleeping.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Sleep Maintenance Efficiency
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
Sleep maintenance efficiency is total sleep time divided by sleep period time (time is measured in minutes).
|
Day 1 (during overnight assessment of the single study visit)
|
|
Time in Each Sleep Stage
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
Time in sleep stages N1, N2, N3 and REM will be measured in minutes.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Number of Arousals
Time Frame: Day 1 (during overnight assessment of the single study visit)
|
The sleep-related parameters obtained from conventional PSG and the NextSense ear-EEG device will be assessed.
Arousals from sleep will be counted.
|
Day 1 (during overnight assessment of the single study visit)
|
|
Sleep Onset Latency to Stage N1 Sleep During MWT
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
The sensitivity of the NextSense ear-EEG device and Ellcie Healthy glasses to detect metrics of daytime sleepiness during conventional MWT testing will be assessed.
Sleep onset latency to stage N1 sleep is the time it takes in minutes to transition from wakefulness to the first stage of sleep.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Sleep Onset Latency to REM Sleep During MWT
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
The sensitivity of the NextSense ear-EEG device and Ellcie Healthy glasses to detect metrics of daytime sleepiness during conventional MWT testing will be assessed.
REM sleep latency is the time it takes in minutes to transition from wakefulness to REM sleep.
|
Day 2 (during daytime assessment of the single study visit)
|
|
EEG Power Spectral Analysis During MWT
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
The sensitivity of the NextSense ear-EEG device and Ellcie Healthy glasses to detect metrics of daytime sleepiness during conventional MWT testing will be assessed.
The EEG signals from PSG and the NextSense ear-EEG device will be analyzed and compared for spectral power within delta, theta, alpha, and beta frequency bands.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Fast Fourier Transformation (FFT) During MWT
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
The sensitivity of the NextSense ear-EEG device and Ellcie Healthy glasses to detect metrics of daytime sleepiness during conventional MWT testing will be assessed.
EEG spectral analysis using the fast Fourier transformation will be compared between EEG signals from PSG and the NextSense ear-EEG device.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Blink Rate
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
The number of blinks per minute will be assessed with the Ellcie Healthy glasses during MWT.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Blink Duration
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
Blink duration (in milliseconds) will be assessed with the Ellcie Healthy glasses during MWT.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Velocity of Eyelid Opening
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
Velocity of eyelid opening, measured as centimeters per second (cm/s), will be assessed with the Ellcie Healthy glasses during MWT.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Velocity of Eyelid Closing
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
Velocity of eyelid closing, measured as centimeters per second (cm/s), will be assessed with the Ellcie Healthy glasses during MWT.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Amplitude
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
Amplitude, measured as the proportion of lid aperture, will be assessed with the Ellcie Healthy glasses during MWT.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Fixation/Saccade Estimation
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
The fixation (milliseconds when the eye is focused on a target) to saccade (rapid eye movement between fixations) estimation will be assessed with the Ellcie Healthy glasses during MWT.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Number of Shifts in Gaze
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
Gaze mobility will be assessed with the Ellcie Healthy glasses during MWT.
The number of changes in eye gaze will be evaluated.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Total Number of Head Bobs
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
Total number of head bobs will be assessed with the Ellcie Healthy glasses during MWT.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Frequency of Head Bobs
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
Frequency of head bobs will be assessed with the Ellcie Healthy glasses during MWT.
|
Day 2 (during daytime assessment of the single study visit)
|
|
Acceleration of Head Bobs
Time Frame: Day 2 (during daytime assessment of the single study visit)
|
Acceleration of head bobs will be assessed with the Ellcie Healthy glasses during MWT.
Head bob acceleration will be measured as angular acceleration in units of angle per unit time squared.
|
Day 2 (during daytime assessment of the single study visit)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Rye, MD, PhD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- STUDY00003148
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep
-
University of Wisconsin, MadisonPhilips HealthcareCompletedSleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization
-
Brain Electrophysiology Laboratory CompanyRecruiting
-
University GhentEuropean CommissionCompleted
-
Mahidol UniversityRamathibodi HospitalNot yet recruitingSleep Inertia | Sleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization | Night Shift WorkThailand
-
Northumbria UniversityCompletedSleep | Mood | Poor Quality Sleep | Good Sleep HabitUnited Kingdom
-
Universidade Federal de PernambucoEnrolling by invitationSleep | Obstructive Sleep Apnea (OSA)Brazil
-
Atlas UniversityCompletedSleep | Surgery | Sleep QualityTurkey (Türkiye)
-
Mersin UniversityCompletedSleep Quality | Sleep PerceptionTurkey (Türkiye)
-
Brigham and Women's HospitalNot yet recruitingObstructive Sleep Apnea | Sleep-disordered BreathingUnited States
-
Institute of Nutrition, Slovenia (Nutris)Valens Int. d.o.o., Slovenija; Faculty of Pharmacy, University of Ljubljana... and other collaboratorsNot yet recruitingSleep Quality | Sleep Onset LatencySlovenia
Clinical Trials on Ellcie Healthy Glasses
-
Emory UniversityNextSense, Inc.Completed
-
Myoptechs, IncUniversity of Waterloo School of Optometry and Vision ScienceNot yet recruitingMyopia: Refractive Error
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting
-
Sara Hazem Mohamed RabieNot yet recruiting
-
Children's Hospital of Fudan UniversityActive, not recruiting
-
University of ArizonaNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruiting
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownPinholeKorea, Republic of
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional Vision ChangesKorea, Republic of
-
Donald O Mutti, OD, PhDCompleted
-
University of Alabama at BirminghamTerminatedConcussion, Mild | Convergence Insufficiency | Accommodation; InsufficiencyUnited States